Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial

K. Ray Chaudhuri^*, Per Odin, Joaquim J. Ferreira, Angelo Antonini, Olivier Rascol, Mónica M. Kurtis, Alexander Storch, Kirsty Bannister, Patrício Soares-da-Silva, Raquel Costa, Diogo Magalhães, José Francisco Rocha

^*Corresponding author for this work

NIHR Maudsley Biomedical Research Centre (BRC)
Basic and Clinical Neuroscience
Wolfson SPaRC

Department of Clinical Sciences
Faculdade de Medicina de Lisboa
University of Padua
CHU Toulouse, CHU de Toulouse, Dept Med Genet
Hospital Ruber Internacional
University Hospital Rostock
BIAL
Universidade do Porto

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

132 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial

Fingerprint

Pharmacology, Toxicology and Pharmaceutical Science